Formulation and evaluation of liquisolid compacts for olmesartan medoxomil. [PDF]
Prajapati ST +4 more
europepmc +1 more source
Comparative efficacy and safety of dual-combination vs. triple-combination antihypertensive therapies in hypertensive patients: an updated meta-analysis of randomized controlled trials. [PDF]
Gong Z, Huang L, Long X, Zhang Y.
europepmc +1 more source
Efficacy and Safety Study of Olmesartan Medoxomil, Amlodipine, and Hydrochlorothiazide Combination Therapy in Patients with Hypertension Not Controlled with Olmesartan Medoxomil and Hydrochlorothiazide Combination Therapy: Results of a Randomized, Double-Blind, Multicenter Trial. [PDF]
Sohn IS +7 more
europepmc +1 more source
Erratum to: Efficacy and Safety Study of Olmesartan Medoxomil, Amlodipine, and Hydrochlorothiazide Combination Therapy in Patients with Hypertension Not Controlled with Olmesartan Medoxomil and Hydrochlorothiazide Combination Therapy: Results of a Randomized, Double-Blind, Multicenter Trial. [PDF]
Sohn IS +7 more
europepmc +1 more source
Frequency and Profiles of Drug Combinations Constituting the Triple Whammy in Japan: An Analysis of a Patient Estimation Database. [PDF]
Maese M +7 more
europepmc +1 more source
Impact of the national centralized volume-based procurement policy on antihypertensive drug procurement, price, and volume in Guangxi: an interrupted time series analysis of procurement data. [PDF]
Liang S +5 more
europepmc +1 more source
A thorough QTc study demonstrates that olmesartan medoxomil does not prolong the QTc interval. [PDF]
Mendell J +3 more
europepmc +1 more source
Pharmacokinetic and Clinical Relevance of the Medoxomil Moiety in Olmesartan: A Scoping Review
Navnit Wadwa +9 more
doaj +1 more source
Olmesartan-associated enteropathy presenting as severe malnutrition. [PDF]
Mpanda A, Sylla M, Young ED.
europepmc +1 more source

